<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149639">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01866488</url>
  </required_header>
  <id_info>
    <org_study_id>12-1027-01</org_study_id>
    <nct_id>NCT01866488</nct_id>
  </id_info>
  <brief_title>The Obstetric Cook Double Balloon Catheter in Combination With Oral Misoprostol for Induction of Labor</brief_title>
  <official_title>The Obstetric Cook Double Balloon Catheter in Combination With Oral Misoprostol for Induction of Labor: A Double-Blinded, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is a randomized, controlled, double-blinded trial of Obstetric Cook
      Catheter combined with oral misoprostol for induction of labor in pregnant patients.  The
      primary outcome to be studied is vaginal delivery rate for the Obstetric Cook Catheter in
      combination with oral placebo and the Obstetric Cook Catheter in combination with oral
      misoprostol. Secondary outcomes to be studied include the safety of the method, composite
      maternal morbidity and composite neonatal morbidity.

      The hypothesis is that there is a higher vaginal delivery rate in the patient whom receive
      both the Obstetric Cook Catheter and the oral misoprostol.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Occurence of cesarean section</measure>
    <time_frame>Within 96 hours from the commencement of the Induction of Labor</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from start of induction of labor to vaginal delivery</measure>
    <time_frame>24, 48 and 72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in cervical bishop score with allotted treatment</measure>
    <time_frame>6 hours</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Labor Induction</condition>
  <arm_group>
    <arm_group_label>Cook Catheter, Oral Misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cook Catheter is placed and a 50mcg misoprostol tablet is given orally. A repeat dose is administered in 3 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cook Catheter, Oral Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cook Catheter is placed and a placebo tablet is given orally. A repeat dose is administered in 3 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <arm_group_label>Cook Catheter, Oral Misoprostol</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Single, live fetus

          2. Cephalic (head-first) presentation

          3. Reassuring fetal health assessment

          4. Gestational age between 23 and 42 weeks

          5. Maternal age 18 and above

          6. Bishop score less than 8 in primigravidae

          7. Bishop score less than 6 in multigravidae

        Exclusion Criteria:

        1.  Fetal demise 2.  Fetal malpresentation 3.  Estimated fetal weight less than 500 grams
        or more than 4000 grams        4.  Placenta previa 5.  Non-reassuring fetal health
        assessment 6.  Active maternal asthma exacerbation requiring additional medications from
        the usual medication requirements.

        7.  History of cesarean section 8.  Rupture of amniotic membrane 9.  Latex allergy 10.
        Spontaneous labor 11. Other contraindication to vaginal delivery 12.  Allergy to
        misoprostol of cook catheter
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meg Hill, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meg Hill, MBBS</last_name>
    <phone>520 626 6174</phone>
    <email>meg.hill@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meg Hill, MBBS</last_name>
      <phone>520-626-6174</phone>
      <email>meg.hill@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Maritza Gonzalez, MD</last_name>
      <phone>520 626 6174</phone>
      <email>mgonzalez@obgyn.arizona.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Meg Hill, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maritza Gonzalez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 28, 2013</lastchanged_date>
  <firstreceived_date>April 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Arizona</investigator_affiliation>
    <investigator_full_name>Meg Hill</investigator_full_name>
    <investigator_title>Fellow, Maternal Fetal Medicine</investigator_title>
  </responsible_party>
  <keyword>Labor induction</keyword>
  <keyword>Misoprostol</keyword>
  <keyword>Cytotec</keyword>
  <keyword>Cook Obstetric Double Balloon Catheter</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
